PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Brunner, Hermine I.
TI  - Tocilizumab Significantly Reduces Flares in Polyarticular Juvenile Idiopathic Arthritis
DP  - 2012  01
TA  - MD Conference Express
PG  - 13--14
VI  - 12
IP  - 19
4099  - http://mdc.sagepub.com/content/12/19/13.short
4100  - http://mdc.sagepub.com/content/12/19/13.full
AB  - Treatment with tocilizumab, a humanized monoclonal antibody that interrupts interleukin-6-mediated signaling, results in meaningful improvement of polyarticular-course juvenile idiopathic arthritis following methotrexate failure, with treatment responses maintained to at least 40 weeks. This article discusses findings from the A Study of Tocilizumab in Patients with Active Polyarticular-Course Juvenile Idiopathic Arthritis [CHERISH; NCT00988221] trial.